Neurotoxicity is one of the most relevant dose-limiting toxicities of the anticancer drug paclitaxel. It exhibits substantial interindividual variability of unknown molecular basis, and represents one of the major challenges for the improvement of paclitaxel therapy. The extensive variability in paclitaxel clearance and metabolism lead us to investigate the association between polymorphisms in paclitaxel elimination pathway and neurotoxicity. We selected 13 relevant polymorphisms in genes encoding paclitaxel metabolizing enzymes (CYP2C8, CYP3A4 and CYP3A5) and transporters (organic anion transporting polypeptide (OATP) 1B1, OATP1B3 and P-glycoprotein) and genotyped them in 118 Spanish cancer patients treated with paclitaxel. After adjusting for age and treatment schedule, CYP2C8 Haplotype C and CYP3A5*3 were associated with protection (hazard ratio (HR) (per allele) ¼ 0.55; 95% confidence interval (CI) ¼ 0.34-0.89; P ¼ 0.014 and HR (per allele) ¼ 0.51; 95%CI ¼ 0.30-0.86; and P ¼ 0.012, respectively) and CYP2C8*3 with increased risk (HR (per allele) ¼ 1.72; 95%CI ¼ 1.05-2.82; and P ¼ 0.032). In each case, the allele causing increased paclitaxel metabolism was associated with increased neurotoxicity, suggesting an important role for metabolism and hydroxylated paclitaxel metabolites. We estimated the HR per paclitaxel-metabolism increasing allele carried across the three polymorphisms to be HR ¼ 1.64 (95% CI ¼ 1.26-2.14; P ¼ 0.0003). The results for P-glycoprotein were inconclusive, and no associations were observed for the other genes studied. The incorporation of this genetic data in treatment selection could help to reduce neurotoxicity events, thereby individualizing paclitaxel pharmacotherapy. These results warrant validation in independent series.
Introduction
Paclitaxel, an extract from the bark of the Pacific yew, Taxus brevifolia, is a chemotherapeutic drug widely used in the treatment of a variety of solid tumors, such as breast, ovarian and lung cancer. 1 Paclitaxel acts through microtubule stabilization, which alters cell motility, transport and cell division, and consequently leads to cell death. 2, 3 The major side-effects of paclitaxel are hematological toxicity (mainly neutropenia) and peripheral neuropathy. The risk of neutropenia has been significantly reduced in recent years by using shorter infusion times and the administration of granulocyte colony stimulating factors. 4, 5 On the other hand, neurotoxicity cannot be prevented nor treated, can last for months, and in severe cases it may cause irreversible nerve damage. 6, 7 exhibits substantial interindividual variability. This toxicity is dose-dependent and more frequent in weekly paclitaxel regimens, 8, 9 in patients with diabetes, previous neurotoxic chemotherapy treatments and in patients with pre-existing neuropathies. 10, 11 Age and gender might also be risk factors [11] [12] [13] and decreased levels of plasma nerve factors might have a role in the neurotoxicity. 14 However, a large part of the variability in neurotoxicity exhibited by patients remains unexplained and is unpredictable. It is interesting to note that decreased paclitaxel clearance is associated with increased neurotoxicity, 11, 15 thus suggesting an important role for drug metabolism and transport in this adverse effect.
Paclitaxel elimination is mediated by hepatic metabolism and biliar excretion (Figure 1) , and great interindividual variability on paclitaxel pharmacokinetics has been reported. [16] [17] [18] In the liver paclitaxel is hydroxylated at the 6a position by cytochrome P450 2C8 (CYP2C8), forming the major metabolite, and at the C3 0 position by CYP3A4/5. 19, 20 Concerning transport, paclitaxel uptake into the hepatocytes is mediated by the organic anion transporting polypeptide (OATP) 1B3 and, to some extent, (OATP) 1B1, 21, 22 and efflux is mediated by P-glycoprotein. 23, 24 The genes encoding these proteins are subjected to relevant genetic variation, which can alter drug metabolism and disposition, as we and others have shown. 17, [25] [26] [27] At present, despite its potential importance for neurotoxicity, very little is known about the genes responsible for the final concentration of paclitaxel and its metabolites in the nervous cells. The association between paclitaxel neurotoxicity and pharmacokinetic parameters 11, 15 leads us to propose that polymorphisms in the genes mediating paclitaxel elimination could contribute to the interindividual differences in this toxicity. So far, three studies addressing this hypothesis and using different strategies have produced contradictory results. One study found higher neurotoxicity for an allele variant of CYP2C8, 15 whereas Sissung et al. 28 and Marsh et al. 29 did not find significant associations for the genes studied. However, two studies had recruited less than 25 patients, and the latter did not take into account the dose-dependent nature of paclitaxel neurotoxicity. This suggests that, despite the important implications on clinical practice, the effect of genetic variation on paclitaxel neurotoxicity is still unclear. In this exploratory study we aimed to address this challenge by designing a pharmacogenetic study that took into account the cumulative nature of the neurotoxicity and other previously described neurotoxicity risk factors. In this study we have examined thirteen key polymorphisms in genes involved in paclitaxel clearance pathway in a series of patients treated with paclitaxel and studied their association with neurotoxicity.
Materials and methods

Patients
A total of 132 cancer patients treated with paclitaxel in the Oncology Unit of the Hospital Alcorcó n were recruited between 2006 and 2008. The study was approved by the Internal Ethical Review Committee of the Hospital Alcorcó n and all patients signed a written informed consent before the collection of blood or saliva. In all, 62 cases were recruited in a retrospective basis (i.e. paclitaxel administration started before the beginning of the study) and 56 prospectively from December 2006 to March 2008. Inclusion criteria were as follows: histologically documented solid neoplasia; chemotherapy regimen including paclitaxel, age more than 18 years, life expectancy of X12 weeks; Eastern Cooperative Oncology Group performance status of 2 or less; no chemotherapy, hormonal therapy nor radiotherapy within 4 weeks before treatment; adequate contraception for women of childbearing potential; and adequate bone marrow, renal and hepatic function. Exclusion criteria were three or more previous chemotherapy regimens, hematological malignancy and previous neuropathy caused by conditions such as alcoholism, diabetes mellitus or peripheral vascular disease.
DNA could not be obtained for 6 patients and key clinical data was not available for 4 patients. In all, 4 patients had clinical conditions that interfered with paclitaxel neurotoxicity evaluation and were excluded from the study: 1 patient had Spanish toxic oil syndrome, another had been diagnosed with multiple sclerosis, another presented residual grade 2 neurotoxicity from previous chemotherapy treatment and 1 patient had a history of alcohol abuse. In total, 118 patients were included in the final analysis. Patient characteristics and the chemotherapy regimens are summarized in Table 1 . The most frequent primary tumor types were lung (n ¼ 39), breast (n ¼ 38) and ovarian cancer (n ¼ 24). A total of 74 patients received paclitaxel as 3-h infusion, whereas 41 patients received this drug as 1-h infusion. A total of 39 patients received treatment with paclitaxel as adjuvant therapy, 4 patients received neoadjuvant (primary therapy) and 75 patients received schemes of chemotherapy with paclitaxel for advanced/ relapsed disease.
Paclitaxel was supplied as a concentrated solution in a mixture of Cremophor EL and ethanol and was administered mainly as 1-h intravenous infusion on weekly schemes and as 3-h intravenous infusion on the first day of the 3-week cycle. The 80-90 mg m À2 paclitaxel scheme consisted of weekly administrations, whereas the 150-175 mg m À2 paclitaxel scheme consisted of administration every 21 days. Standard intravenous premedication consisted of dexamethasone (10 mg), dexclorfeniramina (5 mg) and ranitidine (20 mg), given 30 min before paclitaxel infusion.
Neurotoxicity assessment and inclusion of relevant clinical data Neurotoxicity was evaluated with data collected from the medical records of the patients. Sensitive and motor neurotoxicity was graded according to the National Cancer Institute Common Toxicity Criteria Version 2:
30 sensory neuropathy grade 1 included numbness/paresthesia in the feet, in grade 2 these symptoms were present in both fingers and feet and grade 3 consisted of functional disabling numbness/paresthesia. Motor neuropathy grade 1 was CYP2C8 and CYP3A5 SNPs and paclitaxel neurotoxicity S Leskelä et al defined by weakness in feet, in grade 2 the symptoms were present in both extremities and patients with grade 3 had trouble walking. On the first day of each chemotherapy cycle an evaluation of neurological symptoms (sensory symptoms such as numbness and tingling in fingers of hands and feet; difficulty feeling the shape of objects; and motor symptoms such as general weakness, trouble walking and trouble buttoning buttons) and a physical and neurological examination was carried out. Details of neurotoxicity and modifications to the treatment regimen (dose reductions or suspensions) because of paclitaxel-induced neurotoxicity are shown in Table 2 . The accumulated dose of paclitaxel causing grade 2 neurotoxicity, the total accumulated dose of paclitaxel, and other relevant demographic and clinical data such as age, gender, body surface area, type of paclitaxel treatment, tumor characteristics, comorbidity factors and previous neurotoxic treatments, were included in an anonymous database.
DNA isolation, selection of polymorphisms and genotyping DNA was isolated either from peripheral blood or saliva collected from the patients. For peripheral blood, DNA was isolated using both the FlexiGene DNA Kit (Qiagen, Valencia, CA, USA) and an automatic DNA extraction robot (Magnapure, Roche, Mannheim, Germany) according to the manufacturer's recommended protocols. For DNA extractions from saliva we used Oragene DNA Self-Collection Kits (DNA Genotek Ottawa, ON, Canada). The final DNA concentration was quantified by PicoGreen (Invitrogen, Carlsbad, CA, USA).
Thirteen single-nucleotide polymorphisms (SNPs) were selected in 6 genes involved in paclitaxel metabolism and transport (CYP3A4, CYP3A5, CYP2C8, SLCO1B1, SLCO1B3 CYP2C8 and CYP3A5 SNPs and paclitaxel neurotoxicity S Leskelä et al and ABCB1; see Figure 1 and Table 3 ). The polymorphisms were selected based on: (i) the allele frequency in Caucasians and (ii) evidence of functionality. With respect to the allele frequency, we estimated, based on a sample size of 120 patients, with a prevalence of neurotoxicity of 50%, that we had over 80% power at an a level of 0.05 to detect per-allele risk ratios of at least two for allele frequencies above 5%. The power was less for protective effects (risk ratio40.50) associated with the minor allele, although remained above 80% for allele frequencies above 15%. Table 3 shows the SNPs selected for the study, in all cases the reported minor allele frequencies were greater than 5% in white Europeans. Concerning the functionality, we selected SNPs with published data showing an altered activity and/or expression, additionally; some potentially relevant missense polymorphisms were included. For CYP2C8 several studies have demonstrated that CYP2C8*3 (R139K; K399R) exhibits an altered activity.
31-36 CYP2C8*4 (I264M) has not been associated with an altered enzyme activity, 33 but it encodes a common variant protein which might not have been sufficiently studied. Regarding CYP2C8 haplotypes B and C, represented by CYP2C8*1B (rs7909236) and rs1113129, 25 we recently showed that they conferred an increased and reduced activity, respectively. 25 For CYP3A4 there are no common coding polymorphisms and the only variant repeatedly studied, and in some cases associated with altered activity, 26 is the promoter CYP3A4*1B allele. However, its effect on enzyme activity remains unclear. 26 On the other hand, CYP3A5 is very polymorphic, and its activity in Caucasians is determined by CYP3A5*3 allele through alternative splicing. 37 For the uptake transporters OATP 1B3 and OATP 1B1 we selected missense polymorphisms with reported functional consequences. 17 Finally, for ABCB1 we selected the three most studied variants (1236C4T, 2677G4T and 3435C4T) 27 associated with altered transport and a missense (N21D) polymorphism described in public databases but not previously studied.
Single-nucleotide polymorphisms were genotyped using either KASPar SNP Genotyping System (Kbiosciences, Herts, UK) or the Amplifluor SNPs Genotyping System (Chemicon International, Temecula, CA, USA). In all, 15 ng of DNA was used for the genotyping reactions, which were carried out in duplicates. The sequence Detection System 7900HT (Applied Biosystems, Foster City, CA, USA) was used for fluorescence detection and allele assignment. Positive controls (that is, DNAs with known genotypes) were included in all assays. In addition, 5% of samples representing the three different genotypes (that is, wild-type homozygotes, heterozygotes and variant homozygotes) were confirmed by sequencing and no deviation was observed between the two determinations.
Genotyping was carried out without the knowledge of the clinical outcome. The call rates were very high for the 13 polymorphisms (genotypes were successfully called for between 116 and 118, of the 118 samples). The minor allele frequencies found for the polymorphisms (Table 3) were similar to those available in public databases (for example, Table 3 . The two SLCO1B3 SNPs analyzed were in complete linkage disequilibrium (r 2 ¼ 1.0).
Statistical methods
All statistical analyses were carried out using SPSS software package version 15.0 (SPSS, Chicago, IL, USA). Nominal twosided P-values o0.05 were considered statistically significant. Associations between genotypes and risk of paclitaxel neurotoxicity were first tested for individual polymorphisms using Kaplan-Meier analysis 39 (log-rank test on two degrees of freedom), modelling the cumulative dose of paclitaxel up to the development of grade 2 neurotoxicity. Patients with no or minimal adverse reaction (grade 0/1) were censored at total cumulative dose. Associations with neurotoxicity were also tested in this way for age (quartiles), gender, body surface area (quartiles), paclitaxel treatment regimen (weekly 80-90 mg m À2 versus every 3 weeks scheme 150-175 mg m À2 ), previous neurotoxic treatments, comorbidity factors (diabetes mellitus, alcohol intake, cardiopathy, nephropathy and so on), retrospective versus prospective cases and type of treatment (palliative versus adjuvant or neo-adjuvant). Associations with cumulative dose of paclitaxel up to the development of grade 2 neurotoxicity were also evaluated for each polymorphism using univariable and multivariable Cox regression under a log-additive model, the latter including age and treatment regimen as covariates, as they were found to be independently associated with neurotoxicity. We also evaluated a model including all SNPs for which individual associations were observed, in which the variants associated with increased metabolic activity acted in a log-additive manner, both within and between SNPs. This was done by analyzing the number of such variants carried as a continuous variable.
Results
As expected, we found that the weekly 80-90 mg m À2 paclitaxel schedule was more neurotoxic than the 150-175 mg m À2 scheme administered every 21 days (P ¼ 0.043) (Supplementary Figure 1A) . In addition, patients younger than 50 years showed a significantly higher neurotoxicity than those older than 50 years (P ¼ 0.019) (Supplementary Figure 1B) . The estimated hazard ratio for these two factors were 1.70 (95% confidence interval (CI) ¼ 1.01-2.87) and 2.12 (95% CI ¼ 1.12-4.02), respectively. No evidence of association with neurotoxicity was found for other demographic (for example, gender, body surface area) and clinical factors (for example, type of tumor, previous neurotoxicity treatments and comorbidity factors).
Concerning genetic variables, their allele frequencies did not deviate substantially from those previously described for Caucasians (Table 3) . With respect to their association with paclitaxel neurotoxicity risk three polymorphisms showed statistically significant evidence of association: CYP2C8*3 (Figure 2a) , CYP2C8 haplotype C (Figure 2b ) and CYP3A5*3 ( Figure 2c ) (P ¼ 0.049, 0.049 and 0.010, respectively). Multivariable Cox regression adjusting for treatment schedule and age, gave an estimated hazard ratio of 1.72 (95% CI ¼ 1.05-2.82; P ¼ 0.032) for CYP2C8*3; 0.55 (95% CI ¼ 0.34-0.89; P ¼ 0.014) for CYP2C8 haplotype C and 0.51 (95% CI ¼ 0.30-0.86; P ¼ 0.012) for CYP3A5*3 (see Table 3 ). It is interesting to note that the SNP associated with a high neurotoxicity risk was a high activity allele (CYP2C8*3) and the two SNPs significantly associated with protection were those with a low metabolizing capacity (CYP2C8 haplotype C and CYP3A5*3). The two SNPs in CYP2C8 were not in linkage disequilibrium (r 2 ¼ 0.005) and CYP3A5*3 is located on a different chromosome. Thus, we constructed a model including the three polymorphisms In the hepatocyte, it is metabolized by CYP2C8 to 6a-hydroxypaclitaxel, which is the major metabolite, and by CYP3A to metabolite C3 0 -hydroxypaclitaxel. Paclitaxel and its metabolites either diffuse to plasma or are excreted to the biliar canaliculi by P-glycoprotein.
CYP2C8 and CYP3A5 SNPs and paclitaxel neurotoxicity S Leskelä et al acting in a log-additive, per-allele manner and estimated the hazard ratio per high-paclitaxel metabolizing allele to be 1.64 (95% CI ¼ 1.26-2.14, P ¼ 0.0003) after schedule and age correction (Table 3 and Figure 3 ). No evidence of association was observed for the uptake transporter genes SLCO1B1 and SLCO1B3 nor the ABCB1 efflux pump ( Table 3 ). The statistical analyses were repeated after normalizing the cumulative paclitaxel doses by body surface area (data not shown), without any substantive changes in the results obtained.
Discussion
This pharmacogenetic study was designed to identify genetic variants influencing paclitaxel neurotoxicity. We studied 13 polymorphisms from six key paclitaxel elimination genes in 118 patients treated with paclitaxel, finding a statistically significant association for three cytochrome P450 functional genetic variants. The strategy followed was to select the most relevant polymorphisms, based on their functionality and allele frequency, in the genes essential for paclitaxel hepatic metabolism (CYP2C8, CYP3A4 and CYP3A5) 19, 20 and transport (SLCO1B1, SLCO1B3 and ABCB1) [21] [22] [23] [24] ( Figure 1 ) and assess their association with the paclitaxel dose that caused grade 2 neurotoxicity in our patients. Our data suggests a possible genetic predisposition to the occurrence of paclitaxelinduced neuropathy.
As paclitaxel neurotoxicity is dose-dependent, 13 we calculated the accumulated paclitaxel dose that produced clinically relevant neurotoxicity, rather than just evaluating the presence or lack of neurotoxicity at the end of the treatment. We confirmed that the more dose intense paclitaxel schedule of 80-90 mg m À2 weekly was a risk factor for the neurotoxicity 8, 9 and, although previous results concerning age are inconclusive, 12, 13, 40 we found that patients below 50 years developed greater neuropathy (Supplementary Figure 1) .
We found a statistically significant association for three CYP polymorphisms, CYP2C8*3, CYP2C8 haplotype C and CYP3A5*3 (Table 3) . Initial in vitro studies for CYP2C8*3 suggested a lower activity, 31, 32 but more recent studies in healthy volunteers have repeatedly demonstrated an increased metabolizing capacity for this allele. [33] [34] [35] [36] In contrast, CYP2C8 haplotype C 35, 41 and CYP3A5*3 37 confer a reduced activity. As the polymorphisms conferring a low metabolizing capacity were associated with protection, whereas the allele with increased activity showed a higher neurotoxicity (Figure 2) , and the effects of these polymorphisms were independent, we incorporated them in a single prediction model (risk alleles: rs11572080 A, rs1113129 G and rs776746 G; Table 3 ). As result of combining the three independent alleles, individuals can be classified in seven groups depending on the number of risk alleles. Although inheriting 5 and 6 risk alleles is infrequent in Caucasians, carrying 0-4 is relatively common (frequency 43%), and so, variation at these three loci could explain a substantial proportion of paclitaxel-related neurotoxicity (Figure 3) . In addition to the discussed polymorphisms, CYP3A4*1B showed a tendency towards increased neurotoxicity (P ¼ 0.057). However, CYP3A4*1B is in strong linkage disequilibrium with the functional CYP3A5*1 allele, suggesting that this latter is the causal polymorphism. 37 A recent study by Gandara et al. 42 on paclitaxel-carboplatintreated patients suggests that population-related pharmacogenetic factors could account for ethnic differences in patient outcomes. However, no differences on paclitaxel neurotoxicity could be observed between Asians and US patients. 42 This could be in agreement with our study, as the protective CYP3A5*3 allele is more frequent in Caucasians than in Asians, 37, 42 but CYP2C8*3 risk allele is mainly Caucasian and could counteract the protective effect. 25, 42 The frequency of CYP2C8 haplotype C in different ethnic groups is unclear. 25 Contradictory results have been obtained regarding the effect of genetic variation on paclitaxel neurotoxicity. 15, 28, 29 A large study by Marsh et al. 29 did not find evidence of associations with neurotoxicity for important polymorph- Figure 2 Kaplan-Meier comparisons of cumulative dose of paclitaxel up to the development of grade 2 neurotoxicity, by genotype at SNPs in CYP2C8 and CYP3A5. Patients with: (a) CYP2C8*3 alleles had a significantly higher risk to encounter neurotoxicity; (b) CYP2C8 haplotype C alleles and (c) CYP3A5*3 alleles were associated with protection against neurotoxicity. The log-rank P value is shown. isms in paclitaxel transporters and relevant CYPs. However, a more recent study by Green et al. 15 found a statistically significant association for CYP2C8*3 allele with increased neurotoxicity risk, which is coincident with our findings. The differences among these studies could be caused by the different experimental designs: on the one hand, Green et al. 15 included a reduced number of patients but neurotoxicity was the primary endpoint of the study; 15, 28 and on the other hand, Marsh et al. 29 included a large number of patients recruited into a phase III randomized trial but the cumulative dose of paclitaxel at neurotoxicity onset was not taken into account. In addition, the study by Sissung et al. 28 focused on ABCB1 polymorphisms, could not find significant differences in 22 patients evaluated for neurotoxicity. Some of the genetic markers analyzed in our study (for example, CYP2C8 Haplotype C with relevant functionality 25 ) were not included in the previous analyses. In addition, the neurotoxicity was analyzed taking into account the dose-dependency with paclitaxel (that is, the dose accumulated causing neurotoxicity grade 2), rather than just evaluating the presence or lack of neurotoxicity at the end of the treatment. Limitations of this study include the heterogeneity of the patients in the form of tumor types and treatment regimens and the inclusion of patients in a retrospective basis. Nevertheless, these factors were considered in the statistical analysis without substantial changes of the results.
It is important to note that in our study polymorphisms affecting paclitaxel metabolism were associated with an altered risk of paclitaxel neurotoxicity. If these findings are confirmed, external factors modifying paclitaxel metabolism (for example, enzyme inhibitors) could be used to change the patients' risk of toxicity. The data suggests that the polymorphisms identified might lead to differences in the ratios between hydroxylated metabolites and the active paclitaxel form (unbound paclitaxel) at time-specific points and that this might lead to differences in neurotoxicity risk. This might occur without drastic changes in total paclitaxel clearance as the plasma concentrations of the active unbound paclitaxel and the metabolites are lower than that of bound paclitaxel. Cell death assays have shown that paclitaxel hydroxy metabolites are less active than paclitaxel, 43, 44 but paclitaxel cytotoxicity increases in the presence of non-cytotoxic concentrations of 6a-hydroxypaclitaxel. 45 However, the effect of these molecules in neurons, which might be damaged through an alteration of neurotransmitter trafficking rather than mitosis blockage, [46] [47] [48] have not been described. Furthermore, the concentrations of the hydroxylated metabolites and unbound paclitaxel in plasma have been shown to be in the same range, 49, 50 but the concentrations in the peripheral nervous cells, where the neurotoxic damage occurs, have not been determined. Alternatively, the metabolites might act through indirect mechanisms interfering with paclitaxel action. Further studies addressing these points such as pharmacokinetic analysis taking into account the identified polymorphisms are needed to improve our knowledge about the mechanism underlying the neurotoxicity.
In conclusion, our study, with paclitaxel neurotoxicity as primary endpoint, provides evidence that CYP2C8 haplotype C and CYP3A5*3 are associated with lower risk of paclitaxel-related neurotoxicity and CYP2C8*3 with increased risk. These results warrant independent validation in a larger population before exploiting the clinical applications. If confirmed, these genetic variants could be used to inform treatment selection, providing the basis for an individualized paclitaxel pharmacotherapy. Figure 3 Proposed model for paclitaxel neurotoxicity risk including the three identified polymorphisms CYP2C8*3, CYP2C8-haplotype C and CYP3A5*3 acting in a log-additive, per-allele manner. Patients were classified in three groups according to the number of risk alleles (0-5).
The Kaplan-Meier analysis shows the comparisons of cumulative dose of paclitaxel up to the development of grade 2 neurotoxicity by number of the risk alleles: rs11572080A, rs1113129G and rs776746G. The log-rank P value is shown.
